Abstract
Whole unfractionated heparin can modestly decrease tumor growth, but the dose of heparin is limited by its anticoagulant properties. To overcome this limitation, we modified the chemical structure of heparin and have prepared a heparin derivative by O-acylating low molecular weight heparin with butyric anhydride, producing a more potent antiproliferative compound, which is only weakly anticoagulant so that the dose may be escalated without threat of hemorrhage. In this study, we investigated the effect of this chemically modified heparin, butanoylated heparin, on the growth of lung cancer in vitro and in vivo. We found that butanoylated heparin a) significantly inhibited lung cancer cell proliferation in vitro and lung cancer growth in mice and rats; b) had very low anticoagulant effect; c) had no significant toxicity on heart, liver, kidney and lung; d) significantly although modestly induced apoptosis and decreased expression of the cell proliferation pathway consisting of mutant p53, phospho-Rb and E2F1 expression in the tumor tissues. We also found that butanoylated heparin significantly inhibited CXCL12 and CXCR4 expression, suggesting that CXCL12/CXCR4 axis may be involved in regulation of tumor growth inhibition by heparin. We concluded that chemically modified butanoylated heparin has potent antiproliferative activity against lung cancer and may represent a new chemical therapeutic agent for cancer patients.
Keywords: Heparin, butanoylated, antitumor, lung cancer, mice, rats
Current Cancer Drug Targets
Title: Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Volume: 10 Issue: 2
Author(s): Lunyin Yu, Hari G. Garg, Boyangzi Li, Robert J. Linhardt and Charles A. Hales
Affiliation:
Keywords: Heparin, butanoylated, antitumor, lung cancer, mice, rats
Abstract: Whole unfractionated heparin can modestly decrease tumor growth, but the dose of heparin is limited by its anticoagulant properties. To overcome this limitation, we modified the chemical structure of heparin and have prepared a heparin derivative by O-acylating low molecular weight heparin with butyric anhydride, producing a more potent antiproliferative compound, which is only weakly anticoagulant so that the dose may be escalated without threat of hemorrhage. In this study, we investigated the effect of this chemically modified heparin, butanoylated heparin, on the growth of lung cancer in vitro and in vivo. We found that butanoylated heparin a) significantly inhibited lung cancer cell proliferation in vitro and lung cancer growth in mice and rats; b) had very low anticoagulant effect; c) had no significant toxicity on heart, liver, kidney and lung; d) significantly although modestly induced apoptosis and decreased expression of the cell proliferation pathway consisting of mutant p53, phospho-Rb and E2F1 expression in the tumor tissues. We also found that butanoylated heparin significantly inhibited CXCL12 and CXCR4 expression, suggesting that CXCL12/CXCR4 axis may be involved in regulation of tumor growth inhibition by heparin. We concluded that chemically modified butanoylated heparin has potent antiproliferative activity against lung cancer and may represent a new chemical therapeutic agent for cancer patients.
Export Options
About this article
Cite this article as:
Yu Lunyin, G. Garg Hari, Li Boyangzi, J. Linhardt Robert and A. Hales Charles, Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054176
DOI https://dx.doi.org/10.2174/156800910791054176 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014
Current Drug Targets SUV39H1-Mediated <i>DNMT1</i> is Involved in the Epigenetic Regulation of Smad3 in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Interleukin 20
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Diagnostic Utility of Pleural Fluid Tests in Clinical Practice
Current Respiratory Medicine Reviews G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Functional Genome-wide Analysis: a Technical Review, Its Developments and Its Relevance to Cancer Research
Recent Patents on DNA & Gene Sequences Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force
Current Nanomedicine Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry